coteauBeta Get App

HUM

Humana
$425.42
-0.46% Oct 21 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-42%-18%+6%+30%+54%Oct 2025Oct 2026Apr 2026
HUMSPY
1W
-0.5%
1M
+12.4%
3M
+7.0%
6M
+96.1%
YTD
+67.3%
1Y
+45.7%

Live chart

Loading live chart…

What they do

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management.

Healthcare · Healthcare Plans

For information only · Important disclosures

Grades vs sector

Momentum
72nd percentile in sector
B+
12-1 return: +38.7%
Percentile within its GICS sector across the S&P 1500.
Growth
86th percentile in sector
A-
Revenue growth (YoY): +26.2%
Percentile within its GICS sector across the S&P 1500.
Value
51st percentile in sector
C+
Forward E/P: 4.1% · EBITDA/EV: 8.9%
Percentile within its GICS sector across the S&P 1500.
Profitability
32nd percentile in sector
C-
Profit margin: +0.9% · Return on equity: +6.9%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 65 of 499 · 12-month momentum 48.9%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Centene to Report Q3 Earnings: Buy, Sell or Hold the Stock?
Zacks · 1h ago

Key stats

52-week range$162.46 – $433.50
Valuation and fundamentals

Valuation & fundamentals

Bottom line
Leans expensive
Model read-out from the numbers below, not advice. Score -2 (DCF counts double).
▼DCF (base case)below the price by 21%
•Piotroski F-score5/9
▲Net debt / EBITDA-2.6x

Discounted cash flow

Bear
$236
-44%
growth 7% · disc. 10.2% · term. 2.0%
Base
$336
-21%
growth 12% · disc. 9.2% · term. 2.5%
Bull
$474
+11%
growth 15% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-03-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)
sector median 29.9×
 –
Forward P/E
sector median 17.6×
 –
EV / EBITDA
sector median 15.8×
 –
Price / sales
sector median 3.1×
 –
Price / book
sector median 3.5×
 –
FCF yield
sector median 4.1%
 –

Quality & financial health

Gross margin
–
Operating margin
1.8%
FCF margin
0.9%
Net margin
0.8%
Return on equity
6.1%
Return on invested capital
19.3%
Net debt / EBITDA
-2.6×
Current ratio
1.8×
Interest cover
3.7×
Cash conversion (OCF/NI)
1.6×
Piotroski F-score 5/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FYRevenueNet incomeFree cash flow
2025$129.7B$1.2B$375.0M
2024$117.8B$1.2B$2.4B
2023$106.4B$2.5B$3.0B
2022$92.9B$2.8B$3.5B
2021$83.1B$2.9B$920.0M
2020$77.2B$3.4B$4.7B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +11.8%.

Earnings

Next report: 2026-11-06 · before open · EPS est -1.00
24-1025-0225-0425-0725-1126-0226-0426-07-3.9911.58
EstimateActual (beat)Actual (miss)
ReportEPS estActualSurprise
2026-07-297.007.61+8.8%
2026-04-2910.2010.31+1.1%
2026-02-11-3.99-3.96+0.7%
2025-11-052.833.24+14.6%
2025-07-295.876.27+6.9%
2025-04-3010.0711.58+15.0%
2025-02-11-2.12-2.16-1.9%
2024-10-303.394.16+22.9%

Quarterly revenue

QuarterRevenueYoY
2026-06-30$40.9B+26.2%
2026-03-31$39.6B–
2025-12-31$32.5B–
2025-09-30$32.6B–
2025-06-30$32.4B–
Rating changes
Reiterated
2026-10-13 · Mizuho reiterated Outperform on HUM
Reiterated
2026-10-12 · UBS reiterated Neutral on HUM
Reiterated
2026-10-12 · Truist Securities reiterated Hold on HUM
Reiterated
2026-10-12 · Oppenheimer reiterated Outperform on HUM
Upgrade
2026-10-12 · Raymond James upgraded HUM from Market Perform to Outperform
Reiterated
2026-10-09 · Barclays reiterated Overweight on HUM

Third-party analyst actions, not Coteau's views. All rating changes

Recent dividends

2026-06-26: $0.885 · 2026-03-27: $0.885 · 2025-12-26: $0.885 · 2025-09-26: $0.885 · 2025-06-27: $0.885 · 2025-03-28: $0.885 · 2024-12-31: $0.885 · 2024-09-30: $0.885
Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:06:29 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026